Clinical trial
A Randomized Controlled Trial of Ethanol-gelfoam Mixture(EGM) Versus Gelfoam for the Treatment of Arterioportal Shunts (APS) in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolization (TACE)
NCT02338297 is registered in ClinicalTrials.gov with Nanjing Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Controlled Trial of Ethanol-gelfoam Mixture(EGM) Versus Gelfoam for the Treatment of Arterioportal Shunts (APS) in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolization (TACE)
- Lead sponsor
- Nanjing Medical University
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- February 29, 2016
- Completion date
- December 31, 2017
- Enrollment
- 236 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.